Literature DB >> 10559359

Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.

S Ethelberg1, B D Tzschaschel, A Luz, S J Diaz-Cano, F S Pedersen, J Schmidt.   

Abstract

SL3-3 is a murine leukemia virus which is only weakly bone pathogenic but highly T-cell lymphomagenic. A major pathogenic determinant is the transcriptional enhancer comprising several transcription factor binding sites, among which are three identical sites for nuclear factor 1 (NF1). We have investigated the pathogenic properties of NF1 site enhancer mutants of SL3-3. Two different mutants carrying a 3-bp mutation either in all three NF1 sites or in the central site alone were constructed and assayed in inbred NMRI mice. The wild type and both mutants induced lymphomas in all mice, with a mean latency period of 9 weeks. However, there was a considerable difference in osteopetrosis induction. Wild-type SL3-3 induced osteopetrosis in 11% of the mice (2 of 19), and the triple NF1 site mutant induced osteopetrosis in none of the mice (0 of 19), whereas the single NF1 site mutant induced osteopetrosis in 56% (10 of 18) of the mice, as determined by X-ray analysis. A detailed histological examination of the femurs of the mice was carried out and found to support this diagnosis. Thus, the NF1 sites of SL3-3 are major determinants of osteopetrosis induction, without determining lymphomagenesis. This conclusion was further supported by evaluation of the bone pathogenicity of other SL3-3 enhancer variants, the lymphomagenicity of which had been examined previously. This evaluation furthermore strongly indicated that the core sites, a second group of transcription factor binding sites in the viral enhancer, are necessary for the osteopetrosis induction potential of SL3-3.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559359      PMCID: PMC113096     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity.

Authors:  E E Furlong; T Rein; F Martin
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

2.  Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.

Authors:  A L Zaiman; J Lenz
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  E-box sequence and context-dependent TAL1/SCL modulation of basic helix-loop-helix protein-mediated transcriptional activation.

Authors:  A L Nielsen; P L Norby; F S Pedersen; P Jorgensen
Journal:  J Biol Chem       Date:  1996-12-06       Impact factor: 5.157

4.  Molecular and pathogenic characterization of the RFB osteoma virus: lack of oncogene and induction of osteoma, osteopetrosis, and lymphoma.

Authors:  W Gimbel; J Schmidt; R Brack-Werner; A Luz; P G Strauss; V Erfle; T Werner
Journal:  Virology       Date:  1996-10-15       Impact factor: 3.616

5.  Mapping of a major osteomagenic determinant of murine leukemia virus RFB-14 to non-long terminal repeat sequences.

Authors:  M Ostergaard; L Pedersen; J Schmidt; A Luz; J Lovmand; V Erfle; F S Pedersen; P G Strauss
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  An NF1-like protein functions as a repressor of the von Willebrand factor promoter.

Authors:  N Jahroudi; A M Ardekani; J S Greenberger
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

7.  Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines.

Authors:  A L Nielsen; P L Nørby; F S Pedersen; P Jørgensen
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells.

Authors:  G Wesolowski; L T Duong; P T Lakkakorpi; R M Nagy; K Tezuka; H Tanaka; G A Rodan; S B Rodan
Journal:  Exp Cell Res       Date:  1995-08       Impact factor: 3.905

9.  NFI/X proteins: a class of NFI family of transcription factors with positive and negative regulatory domains.

Authors:  G Nebl; A C Cato
Journal:  Cell Mol Biol Res       Date:  1995

10.  A proline-rich TGF-beta-responsive transcriptional activator interacts with histone H3.

Authors:  A Alevizopoulos; Y Dusserre; M Tsai-Pflugfelder; T von der Weid; W Wahli; N Mermod
Journal:  Genes Dev       Date:  1995-12-15       Impact factor: 11.361

View more
  4 in total

1.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

3.  RANKL-RANK signaling regulates expression of xenotropic and polytropic virus receptor (XPR1) in osteoclasts.

Authors:  Parul Sharma; Somying Patntirapong; Steven Hann; Peter V Hauschka
Journal:  Biochem Biophys Res Commun       Date:  2010-07-13       Impact factor: 3.575

4.  Identification of novel Bach2 transcripts and protein isoforms through tagging analysis of retroviral integrations in B-cell lymphomas.

Authors:  Jinghua Liu; Annette Balle Sørensen; Bruce Wang; Matthias Wabl; Anders Lade Nielsen; Finn Skou Pedersen
Journal:  BMC Mol Biol       Date:  2009-01-21       Impact factor: 2.946

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.